Please assess the completion status of the following clinical trial:

Trial Title: Anti-inflammatory H1 Antihistamines Allergic Rhinitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* persistent allergic rhinitis~Exclusion Criteria:~* the presence of asthma or nasal polyps,~* acute and chronic upper respiratory infections,~* administration of intranasal or systemic corticosteroids or H1 antihistamines in the past 30 days.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- healthy volunteers (Type: NO_INTERVENTION): healthy volunteers
- Desloratadine (Type: ACTIVE_COMPARATOR): patients with allergic rhinitis under treatment with Desloratadine 5 mg/day, 4 weeks
- Levocetirizine (Type: ACTIVE_COMPARATOR): patients with allergic rhinitis under treatment with Levocetirizine 5 mg/day, 4 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).